NexCure Raises $19M Series A Led by RA Capital to Expand Outpatient Cell and Gene Therapy Platform 

NexCure, a Boston-based healthcare infrastructure startup focused on expanding access to advanced cell and gene therapies, has raised $19 million in Series A funding as it builds an outpatient care delivery platform designed to bring complex treatments such as CAR-T therapy closer to patients.

The round was led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures. The financing supports NexCure’s mission to address major bottlenecks in oncology care delivery, particularly the limited number of hospitals capable of administering highly specialized therapies.

NexCure was founded by Raven, the healthcare incubator affiliated with RA Capital Management, to solve a critical structural issue in the U.S. healthcare system: the concentration of advanced therapy delivery in a small number of academic medical centers. According to the company, out of approximately 6,100 hospitals in the United States, only about 200 currently administer CAR-T therapy, leaving the vast majority of patients without local access to these potentially life-saving treatments.

The company is building a hybrid model that combines purpose-built outpatient clinics with a proprietary software platform that standardizes and coordinates complex clinical workflows. Its system is designed to support therapies that require intensive monitoring, strict protocols, and coordinated care teams, enabling treatment delivery in community-based settings rather than only large academic hospitals.

NexCure’s platform integrates clinical decision support, remote monitoring, and operational intelligence tools to reduce variability in care delivery. By standardizing protocols across treatment sites, the company aims to ensure safety and consistency while scaling access to advanced oncology therapies. The approach is intended to serve patients, referring oncologists, health systems, payers, and pharmaceutical manufacturers seeking more efficient and geographically distributed care models.

The company’s leadership includes Sophie Papa, FRCP, PhD, who serves as Founder and Chief Medical Officer. NexCure’s strategy is grounded in clinical experience with cell therapies and reflects a broader effort to move complex oncology treatments closer to patients’ homes while maintaining the rigorous standards required for safe administration.

Investor interest in NexCure reflects growing momentum in healthcare infrastructure startups that address system-level inefficiencies rather than focusing solely on drug development. Venture firms such as RA Capital have increasingly backed companies that combine clinical operations with software platforms to improve scalability and access in high-cost therapeutic areas like oncology and immunology.

The capital raised will be used to expand NexCure’s outpatient clinic network, enhance its proprietary care delivery platform, and support operational scaling of its integrated treatment model. The company is also expected to invest in building partnerships across the healthcare ecosystem, including hospitals, payers, and pharmaceutical companies involved in cell and gene therapy distribution.

As CAR-T and other advanced therapies continue to expand into new disease areas beyond oncology, NexCure is positioning itself as a foundational infrastructure provider for next-generation treatment delivery. Its goal is to transform how complex therapies are administered by shifting care from centralized academic centers to distributed, community-based settings supported by standardized digital systems.

With its Series A funding in place, NexCure is now focused on scaling its operational model and building what it describes as a “care delivery operating system” for advanced therapeutics, aiming to significantly expand patient access to some of the most sophisticated treatments in modern medicine.